Developer docs
API playgroundTry for free, no card

Search company profiles

Graphite Bio

Full company profile

uuid0000fgb

Namestring
Graphite Bio
Legal namestring
Graphite Bio
Websiteurl
graphitebio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Graphite Bio was a clinical-stage biotechnology company developing CRISPR/Cas9-based ex vivo gene-edited cell therapies, with its lead program GPH101 aimed at sickle cell disease (SCD) by correcting the disease-causing HBB gene mutation in autologous hematopoietic stem cells. Founded in 2020 and headquartered in South San Francisco, the company was built on foundational research from co-founders including Stanford's Dr. Matthew Porteus, a recognized leader in therapeutic genome editing. The business model was a pre-revenue, capital-intensive biotech playbook: raise venture and public equity, advance a single asset through early clinical development, and target eventual partnership, acquisition, or commercialization with a larger biopharma player.

Operationally, the company concentrated its resources on GPH101, which entered a Phase 1/2 CEDAR trial in SCD. The company went public on NASDAQ in mid-2021 (ticker GRPH) and raised approximately $150.7 million in a financing round shortly thereafter, on top of a $45 million Series A in September 2020. In early 2023, Graphite Bio voluntarily paused the CEDAR trial following a serious adverse event (prolonged cytopenia) in a treated patient, materially damaging the program's risk profile. Subsequently, the company delisted from NASDAQ and its corporate web presence appears to have been absorbed by or transferred to LENZ Therapeutics, an unrelated ophthalmology-focused biotech, indicating effective cessation of independent operations as a gene editing entity.

Short descriptiontext

Graphite Bio was a pre-revenue, clinical-stage gene editing company developing CRISPR-based ex vivo cell therapies, with lead candidate GPH101 aimed at correcting the sickle cell disease mutation in autologous hematopoietic stem cells.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gene editing therapy, cell therapy development, CRISPR biotechnology, sickle cell treatment, genetic disease therapeutics
Industry3 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy Biopharmaceuticals
No data
Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Graphite Bio is a biotechnology company developing ex vivo gene-edited cell therapies, with its lead product candidate GPH101 designed to correct the HBB gene mutation in patient-derived stem cells and restore normal adult hemoglobin production for the treatment of sickle cell disease. The therapy involves extracting a patient's hematopoietic stem cells, editing them using a CRISPR-based platform, and reinfusing the corrected cells. GPH101's clinical development was voluntarily paused in early 2023 after patients experienced adverse side effects.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Clinical trials for GPH101 were voluntarily paused in early 2023 after patients developed adverse side effects, halting development progress
Product overview1 text field

Graphite Bio is a biotechnology company developing gene-editing therapies. The company's primary product candidate is GPH101, an ex vivo gene-edited cell therapy for sickle cell disease that aims to correct the HBB gene mutation to restore normal adult hemoglobin production.

Product and service1 record
1GPH101
CategoryGene Therapy
Description

An ex vivo gene-edited cell therapy candidate for sickle cell disease designed to correct the HBB gene mutation in patient-derived hematopoietic stem cells to restore normal adult hemoglobin production. Development was halted following voluntary trial pause in early 2023 due to adverse patient events.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-developer of Casgevy (exagamglogene autotemcel) with Vertex, the first FDA-approved CRISPR-based ex vivo gene-edited cell therapy for sickle cell disease. Most direct competitor to Graphite Bio's GPH101, using a BCL11A erythroid-enhancer disruption approach in patient HSCs.

TypeDirect peer
Description

Developed EDIT-301 (reni-cel), an ex vivo CRISPR-edited HSC therapy for sickle cell disease and beta-thalassemia. Direct competitor to Graphite Bio in autologous HSC gene editing for hemoglobinopathies, also paused/wound down in 2023 amid safety and strategic challenges.

TypeBroad incumbent
Description

Commercialization partner for Casgevy and a dominant rare-disease biotech with established commercial infrastructure for gene and cell therapies. Represents both the dominant competitive force and a potential strategic acquirer for assets like GPH101.

TypeEmerging player
Description

Pioneering base-editing platform developing HSC-targeted therapies for sickle cell disease (BEAM-101) using a different precision gene-editing modality. Comparable in target indication, modality (autologous HSC editing), and clinical stage, with a differentiated chemistry approach.

TypeEmerging player
Description

Clinical-stage CRISPR/Cas9 company developing both in vivo and ex vivo gene-editing therapies across multiple indications. Comparable as a peer gene-editing platform with overlapping scientific founders and investors, though currently focused on in vivo applications.

TypeDirect peer
Description

Pioneer in genome editing using zinc finger nucleases (ZFN), with multiple ex vivo autologous cell therapy programs for hemoglobinopathies including BIVV003 for sickle cell disease. Direct peer in autologous HSC gene editing for sickle cell.

TypeEmerging player
Description

Developer of prime editing, a next-generation precision gene-editing modality applicable to sickle cell disease (potential ex vivo HSC correction). Comparable as a clinical-stage gene-editing peer with similar therapeutic ambitions and modality profile.

TypeEmerging player
Description

Clinical-stage precision gene-editing company focused on cardiovascular disease using both base editing and in vivo CRISPR approaches. Comparable as a next-generation gene-editing platform developer with shared scientific approach and investor base.

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T and gene-editing platform using CRISPR-based chRDNA technology. Comparable as a CRISPR-platform peer with cell therapy applications, though focused on oncology rather than hemoglobinopathies.

TypeEmerging player
Description

Clinical-stage gene-editing and CAR-T company using TALEN-based gene editing for both autologous and allogeneic cell therapies. Comparable as a peer in ex vivo gene-edited cell therapy development, with overlapping platform technology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Graphite Bio

Gene Therapy Biopharmaceuticalsgraphitebio.com

Graphite Bio was a pre-revenue, clinical-stage gene editing company developing CRISPR-based ex vivo cell therapies, with lead candidate GPH101 aimed at correcting the sickle cell disease mutation in autologous hematopoietic stem cells.

What Graphite Bio does

Graphite Bio was a clinical-stage biotechnology company developing CRISPR/Cas9-based ex vivo gene-edited cell therapies, with its lead program GPH101 aimed at sickle cell disease (SCD) by correcting the disease-causing HBB gene mutation in autologous hematopoietic stem cells. Founded in 2020 and headquartered in South San Francisco, the company was built on foundational research from co-founders including Stanford's Dr. Matthew Porteus, a recognized leader in therapeutic genome editing. The business model was a pre-revenue, capital-intensive biotech playbook: raise venture and public equity, advance a single asset through early clinical development, and target eventual partnership, acquisition, or commercialization with a larger biopharma player.

Operationally, the company concentrated its resources on GPH101, which entered a Phase 1/2 CEDAR trial in SCD. The company went public on NASDAQ in mid-2021 (ticker GRPH) and raised approximately $150.7 million in a financing round shortly thereafter, on top of a $45 million Series A in September 2020. In early 2023, Graphite Bio voluntarily paused the CEDAR trial following a serious adverse event (prolonged cytopenia) in a treated patient, materially damaging the program's risk profile. Subsequently, the company delisted from NASDAQ and its corporate web presence appears to have been absorbed by or transferred to LENZ Therapeutics, an unrelated ophthalmology-focused biotech, indicating effective cessation of independent operations as a gene editing entity.

Graphite Bio firmographics

Firmographics
Name
Graphite Bio
Legal name
Graphite Bio
Website
https://graphitebio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Graphite Bio was a pre-revenue, clinical-stage gene editing company developing CRISPR-based ex vivo cell therapies, with lead candidate GPH101 aimed at correcting the sickle cell disease mutation in autologous hematopoietic stem cells.
Ownership category
akta.pro rank

Graphite Bio industry classification

Industry
Product category
Gene Therapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Gene editing therapy
  • Cell therapy development
  • CRISPR biotechnology
  • Sickle cell treatment
  • Genetic disease therapeutics

Where Graphite Bio is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Markets served

Graphite Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Graphite Bio product offering

Product offering

Core offering

Graphite Bio is a biotechnology company developing ex vivo gene-edited cell therapies, with its lead product candidate GPH101 designed to correct the HBB gene mutation in patient-derived stem cells and restore normal adult hemoglobin production for the treatment of sickle cell disease. The therapy involves extracting a patient's hematopoietic stem cells, editing them using a CRISPR-based platform, and reinfusing the corrected cells. GPH101's clinical development was voluntarily paused in early 2023 after patients experienced adverse side effects.

Product overview

Graphite Bio is a biotechnology company developing gene-editing therapies. The company's primary product candidate is GPH101, an ex vivo gene-edited cell therapy for sickle cell disease that aims to correct the HBB gene mutation to restore normal adult hemoglobin production.

Differentiator

Problem solved

Functional benefit

Products and services

  • GPH101 An ex vivo gene-edited cell therapy candidate for sickle cell disease designed to correct the HBB gene mutation in patient-derived hematopoietic stem cells to restore normal adult hemoglobin production. Development was halted following voluntary trial pause in early 2023 due to adverse patient events.

Quantifiable outcome

  • Clinical trials for GPH101 were voluntarily paused in early 2023 after patients developed adverse side effects, halting development progress

Companies that use Graphite Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Graphite Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Graphite Bio partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

Graphite Bio competitors and assessment

Company assessment

Direct peers

  • CRISPR Therapeutics: Co-developer of Casgevy (exagamglogene autotemcel) with Vertex, the first FDA-approved CRISPR-based ex vivo gene-edited cell therapy for sickle cell disease. Most direct competitor to Graphite Bio's GPH101, using a BCL11A erythroid-enhancer disruption approach in patient HSCs.
  • Editas Medicine: Developed EDIT-301 (reni-cel), an ex vivo CRISPR-edited HSC therapy for sickle cell disease and beta-thalassemia. Direct competitor to Graphite Bio in autologous HSC gene editing for hemoglobinopathies, also paused/wound down in 2023 amid safety and strategic challenges.
  • Sangamo Therapeutics: Pioneer in genome editing using zinc finger nucleases (ZFN), with multiple ex vivo autologous cell therapy programs for hemoglobinopathies including BIVV003 for sickle cell disease. Direct peer in autologous HSC gene editing for sickle cell.

Broad incumbents

  • Vertex Pharmaceuticals: Commercialization partner for Casgevy and a dominant rare-disease biotech with established commercial infrastructure for gene and cell therapies. Represents both the dominant competitive force and a potential strategic acquirer for assets like GPH101.

Emerging players

  • Beam Therapeutics: Pioneering base-editing platform developing HSC-targeted therapies for sickle cell disease (BEAM-101) using a different precision gene-editing modality. Comparable in target indication, modality (autologous HSC editing), and clinical stage, with a differentiated chemistry approach.
  • Intellia Therapeutics: Clinical-stage CRISPR/Cas9 company developing both in vivo and ex vivo gene-editing therapies across multiple indications. Comparable as a peer gene-editing platform with overlapping scientific founders and investors, though currently focused on in vivo applications.
  • Prime Medicine: Developer of prime editing, a next-generation precision gene-editing modality applicable to sickle cell disease (potential ex vivo HSC correction). Comparable as a clinical-stage gene-editing peer with similar therapeutic ambitions and modality profile.
  • Verve Therapeutics: Clinical-stage precision gene-editing company focused on cardiovascular disease using both base editing and in vivo CRISPR approaches. Comparable as a next-generation gene-editing platform developer with shared scientific approach and investor base.
  • Caribou Biosciences: Clinical-stage allogeneic CAR-T and gene-editing platform using CRISPR-based chRDNA technology. Comparable as a CRISPR-platform peer with cell therapy applications, though focused on oncology rather than hemoglobinopathies.
  • Cellectis: Clinical-stage gene-editing and CAR-T company using TALEN-based gene editing for both autologous and allogeneic cell therapies. Comparable as a peer in ex vivo gene-edited cell therapy development, with overlapping platform technology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Graphite Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Graphite Bio leadership team

Management profile

Number of profiles

Profiles9 records

Graphite Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Graphite Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Graphite Bio

What does Graphite Bio do?

Graphite Bio is a biotechnology company developing ex vivo gene-edited cell therapies, with its lead product candidate GPH101 designed to correct the HBB gene mutation in patient-derived stem cells and restore normal adult hemoglobin production for the treatment of sickle cell disease. The therapy involves extracting a patient's hematopoietic stem cells, editing them using a CRISPR-based platform, and reinfusing the corrected cells. GPH101's clinical development was voluntarily paused in early 2023 after patients experienced adverse side effects.

When was Graphite Bio founded?

Graphite Bio was founded in 2020. It employs 51 to 100 people.

Where is Graphite Bio based?

Graphite Bio is headquartered in South San Francisco, United States, in the North America region.

Who are Graphite Bio's main competitors?

Direct peers on record are CRISPR Therapeutics, Editas Medicine and Sangamo Therapeutics. Vertex Pharmaceuticals is listed as a broad incumbent. Emerging players are Beam Therapeutics, Intellia Therapeutics, Prime Medicine, Verve Therapeutics, Caribou Biosciences and Cellectis.

Does Graphite Bio have an API?

No public API is recorded for Graphite Bio.

What industry is Graphite Bio in?

Graphite Bio's product category is Gene Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynthegoCRISPR Sickle Cell Gene Therapy: Approaches, Challenges, and ProgressThis educational article provides a comprehensive overview of CRISPR-based gene therapies for sickle cell disease, covering the genetic cause of the disorder, current treatment limitations, and two main therapeutic approaches: correcting the HBB gene mutation to restore normal adult hemoglobin, and knocking out the BCL11A gene to promote fetal hemoglobin production. The article details key clinical trials including Casgevy (CTX001), developed by CRISPR Therapeutics and Vertex Pharmaceuticals, which received FDA approval in December 2023 as the first CRISPR-based therapy, as well as Editas Medicine's EDIT-301 and Graphite Bio's GPH101, the latter of which was voluntarily paused in early 2023 after patients developed adverse side effects. The content discusses the ex vivo gene-edited cell therapy procedure involving extraction, correction, and reinfusion of patient stem cells, with several trials advancing through Phase I/II stages.Business Wire BlogLENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate ProgressLENZ Therapeutics completed its merger with Graphite Bio, trading on Nasdaq under the ticker LENZ on March 22, 2024. The combined company has about $210 million in cash, including $53.5 million from a PIPE, and expects topline results from Phase 3 CLARITY trials in April 2024. It plans to submit an NDA to the FDA in mid-2024.Lenz-TxLENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate ProgressLENZ Therapeutics has completed its merger with Graphite Bio, resulting in a combined entity that will trade on Nasdaq under the ticker symbol "LENZ" starting March 22, 2024. The transaction includes a $53.5 million private placement investment, bringing the company's total cash and cash equivalents to approximately $210 million. LENZ expects to report topline data from its Phase 3 CLARITY trials for presbyopia treatments LNZ100 and LNZ101 in April 2024, with plans to submit a New Drug Application to the FDA by mid-year.YahooSickle Cell Disease Treatment Market Trends Report 2023-2030, Featuring Profiles of Novartis, Pfizer, GlycoMimetics, Emmaus Medical, Bristol-Myers Squibb, CRISPR Therapeutics & Graphite BioThe global sickle cell disease treatment market is projected to reach $9.63 billion by 2030, growing at a 32.33% CAGR from 2023 to 2030. Blood transfusion led the treatment segment in 2022, and North America held over 38% of the market share that year.Business Wire BlogLENZ Therapeutics and Graphite Bio Announce Merger AgreementLENZ Therapeutics and Graphite Bio have entered into a definitive all-stock merger agreement to create a combined, Nasdaq-listed biopharmaceutical company focused on advancing treatments for presbyopia. The transaction includes a concurrent $53.5 million PIPE financing, resulting in an expected cash position of approximately $225 million at closing, with the combined entity anticipated to trade under the ticker "LENZ" in early 2024.GenengnewsHit Pause: The Read-Across to Graphite Bio’s CEDAR Sickle Cell Trial SuspensionGraphite Bio voluntarily paused its Phase I/II CEDAR trial of nula-cel for sickle cell disease after the first patient developed prolonged pancytopenia requiring transfusion and growth factor support. The decision caused the stock to fall nearly 40% to $1.85, and the company will not seek FDA approval for its other therapy GPH102 by mid-2024.BioSpaceGraphite Bio Cuts Sickle Cell Therapy, Half of StaffGraphite Bio is discontinuing development of its sickle cell gene therapy nula-cel and cutting about 50% of its workforce. The company cited the time and resources needed to resume the CEDAR trial and the evolving treatment landscape. It will explore external development for nula-cel and continue its non-genotoxic conditioning program.BenzingaTop 5 Health Care Stocks That May Surge - Fate Therapeutics (NASDAQ:FATE)This article presents a list of oversold healthcare stocks based on RSI (Relative Strength Index) momentum indicators, screening for companies with RSI values near or below 30. The stocks covered include Vera Therapeutics, Fate Therapeutics, Century Therapeutics, Third Harmonic Bio, and Graphite Bio, with corresponding price actions and analyst ratings. Notably, Graphite Bio voluntarily paused its Phase 1/2 CEDAR clinical trial for sickle cell disease due to a serious adverse event in the first patient dosed.Business InsiderA tiny biotech just suffered a safety scare in a gene-editing trial, raising 3 big questions for the entire CRISPR fieldGraphite Bio paused its gene-editing trial for sickle cell disease after a patient's red blood cells and platelets failed to recover. The company's stock fell nearly 40% on the news, and the cause of the side effect is under investigation. The future of its nula-cel program and the company's financial outlook remain uncertain.